Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povidone-iodine 2% vs Artificial Tears for Adenoviral Keratoconjunctivitis
NCT04041856Phase 2
Key facts
- Status
- Unknown
- Start
- Aug 2019
- Primary completion
- Oct 2019
- Sponsor
- Farabi Eye Hospital
- Modality
- Small Molecules
- Conditions
- adenoviral keratoconjunctivitis (EKC)
01
Overview
Phase 2, randomised, open-label trial of povidone-iodine 2% ophthalmic solution in adenoviral keratoconjunctivitis (EKC) (2 arms), sponsored by Farabi Eye Hospital. Primary endpoints: Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis at 3 months and Povidone-iodine 2% eye drop at 3 months. Status: unknown.
02
Design
2 arms- Study design
- RandomizedOpen-label
EKC patients
Povidone-iodine 2% eye drop four times a day
Control group
Artificial tear drops (observational)
03
Who it enrols
Patients suspected for viral conjunctivitis, aged 17 and older, without allergy to iodized materials.
04
Endpoints
Primary
Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis
Povidone-iodine 2% eye drop
Beyond the preview
Go deeper on NCT04041856.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04041856.